Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 4/20 | 0.58 |
| ▸ | PGK1 | P00558 | 1/20 | 0.52 |
| ▸ | PGK2 | P07205 | 1/20 | 0.52 |
| ▸ | MPI | P34949 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5518494 | 1.00 | PGD (0.58) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL20475921 | 1.00 | PGD (0.58) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL7748001 | 1.00 | PGD (0.58) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL7063376 | 0.98 | PGD (0.56) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL7061119 | 0.98 | PGD (0.56) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL7063015 | 0.98 | PGD (0.56) | PGDPGK1PGK2MPISLC22A6 | |
| SCHEMBL7063006 | 0.96 | PGD (0.55) | PGDPGK1PGK2MPI | |
| SCHEMBL7063008 | 0.96 | PGD (0.55) | PGDPGK1PGK2MPI | |
| SCHEMBL321570 | 0.85 | PGD (0.55) | PGDPGK1PGK2MPI | |
| SCHEMBL2619139 | 0.85 | PGD (0.55) | PGDPGK1PGK2MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6583258-B1 | Transesterification catalyst is a salt of adenosine 5'-monophosphate or 2-deoxy-6-phosphogluconic acid; diaryl carbonate with a dihydroxy aromatic compound; bisphenol A with diphenyl carbonate | GENERAL ELECTRIC COMPANY | 2003-06-24 | — | — | US | claimed |
| EP-4650780-A2 | COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS | Flagship Pioneering Innovations VII, LLC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250320254-A1 | Compositions and Methods for Modulating Circulating Factors | FLAGSHIP PIONEERING INNOVATIONS VII LLC (US) | 2025-10-16 | — | — | US | disclosed |
| CN-120035678-A | Compositions and methods for modulating circulation factors | 旗舰创业创新第七有限责任公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4532768-A2 | COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS | Flagship Pioneering Innovations VII, LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023230578-A2 | COMPOSITIONS AND METHODS FOR MODULATING CIRCULATING FACTORS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20130332133-A1 | Classification of Protein Sequences and Uses of Classified Proteins | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2013-12-12 | — | — | US | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20050191627-A1 | Enzymes | INCYTE CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050118594-A1 | Enzymes | CHAWLA NARINDER K (US) | 2005-06-02 | — | — | US | disclosed |
| WO-2003072729-A2 | ENZYMES | INCYTE CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003052075-A2 | ENZYMES | INCYTE GENOMICS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| EP-1320585-A2 | OXIDOREDUCTASES | Incyte Genomics, Inc. (US) | 2003-06-25 | — | — | EP | disclosed |
| US-6583258-B1 | Transesterification catalyst is a salt of adenosine 5'-monophosphate or 2-deoxy-6-phosphogluconic acid; diaryl carbonate with a dihydroxy aromatic compound; bisphenol A with diphenyl carbonate | GENERAL ELECTRIC COMPANY | 2003-06-24 | — | — | US | disclosed |
| WO-2003042357-A2 | ENZYMES | INCYTE GENOMICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002083873-A2 | ENZYMES | INCYTE GENOMICS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002064795-A2 | PUTATIVE HUMAN ENZYMES | INCYTE GENOMICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002050284-A2 | OXIDOREDUCTASES | INCYTE GENOMICS, INC. (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002026951-A2 | OXIDOREDUCTASES | INCYTE GENOMICS INC (US) | 2002-04-04 | — | — | WO | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | PGD 3137/4885PGK1 3003/4885PGK2 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.